What is claimed is:

1. An injection vehicle comprising hyaluronic acid or a derivative thereof at a concentration of about 0.01 to about 0.8 percent by volume.

2. The injection vehicle of Claim 1, wherein the injection vehicle comprises hyaluronic acid.

3. The injection vehicle of Claim 1, wherein the hyaluronic acid or derivative thereof is dissolved in physiological saline.

4. A pharmaceutical formulation comprising:

(a) an effective amount of a biologically active agent in particulate form or coated on, dispersed within, or accompanied by particles; and

(b) an injection vehicle comprising hyaluronic acid or a derivative thereof.

5. The pharmaceutical formulation of Claim 4 wherein the biologically active agent dispersed within particles comprising a biocompatible polymeric matrix.

6. The pharmaceutical formulation of Claim 5, wherein the injection vehicle comprises hyaluronic acid.

7. The pharmaceutical formulation of Claim 6, wherein the concentration of hyaluronic acid is between about 0.01 and about 0.8 percent weight per volume.

8. The pharmaceutical formulation of Claim 6, wherein the hyaluronic acid is dissolved in physiological saline.

9. The pharmaceutical formulation of Claim 6, wherein the polymer matrix comprises a polymer selected from the group consisting of a biodegradable polymer, a non-

biodegradable polymer, a mixture of biodegradable and non-biodegradable polymers, and a copolymer comprising biodegradable and non-biodegradable units.

10. The pharmaceutical formulation of Claim 6, wherein the polymeric matrix comprises a polymer selected from the group consisting of blocked polymers, unblocked polymers, and mixtures thereof.

11. The pharmaceutical formulation of Claim 6, wherein the polymeric matrix comprises a polymer selected from the group consisting of a poly(glycolide); a poly(lactide-co-glycolide); a poly(lactic acid); a poly(glycolic acid); a poly(lactic acid-co-glycolic acid); a polyanhydride; a polyorthoester; a polyetherester; a polycaprolactone; a polyesteramide; a block copolymer of polyethylene glycol and lactide or glycolide; and a blend or copolymer thereof.

12. The pharmaceutical formulation of Claim 11, wherein the polymer is a poly(lactide-co-glycolide) polymer.

13. The pharmaceutical formulation of Claim 6, wherein the biologically active agent is a polypeptide.

14. The pharmaceutical formulation of Claim 11, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-vascular endothelial growth factor Fab (anti-VEGF Fab), a glucagon-like peptide I (GLP-I), a nerve growth factor, and an insulin-like growth factor.

15. The pharmaceutical formulation of Claim 6, wherein the concentration of the polymeric matrix comprising the biologically active agent is between at least about 1 mg/mL to about 500 mg/mL of formulation.

16. The pharmaceutical formulation of Claim 15, wherein the concentration of the polymeric matrix comprising the biologically active agent is between at least about 1 mg/mL to about 300 mg/mL of formulation.

17. A pharmaceutical formulation comprising:

(a) particles comprising a biocompatible polymeric matrix comprising a poly(lactide-co-glycolide) polymer;

(b) an effective amount of a biologically active polypeptide dispersed within the polymeric matrix; and

(c) an injection vehicle comprising hyaluronic acid or a derivative thereof.

18. A method for producing a pharmaceutical formulation comprising:

adding an effective amount of a biologically active agent in particulate form or coated on, dispersed within, or accompanied by particles

to an injection vehicle comprising hyaluronic acid or a derivative thereof.

19. The method of Claim 18 wherein the injection vehicle comprises hyaluronic acid.

20. A method for administering a pharmaceutical formulation of Claim 17 comprising injecting the pharmaceutical formulation through a 23-gauge or smaller needle.

Add B3
Add B2
Add B1